470 related articles for article (PubMed ID: 25428920)
1. Virological failure after 1 year of first-line ART is not associated with HIV minority drug resistance in rural Cameroon .
Zoufaly A; Jochum J; Hammerl R; Nassimi N; Raymond Y; Burchard GD; Schmiedel S; Drexler JF; Campbell NK; Taka N; Awasom C; Metzner KJ; van Lunzen J; Feldt T
J Antimicrob Chemother; 2015 Mar; 70(3):922-5. PubMed ID: 25428920
[TBL] [Abstract][Full Text] [Related]
2. Determinants of HIV-1 drug resistance in treatment-naïve patients and its clinical implications in an antiretroviral treatment program in Cameroon.
Zoufaly A; Jochum J; Hammerl R; Nassimi N; Raymond Y; Burchard GD; Schmiedel S; Drexler JF; Kay CN; Taka N; Awasom C; Metzner K; Jan vL; Feldt T
J Int AIDS Soc; 2014; 17(4 Suppl 3):19615. PubMed ID: 25394119
[TBL] [Abstract][Full Text] [Related]
3. Virological failure and drug resistance during first line anti-retroviral treatment in Indonesia.
Fibriani A; Wisaksana R; Indrati A; Hartantri Y; van de Vijver D; Schutten M; Alisjahbana B; Sudjana P; Boucher CA; van Crevel R; van der Ven A
J Med Virol; 2013 Aug; 85(8):1394-401. PubMed ID: 23722251
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and determinants of virological failure in HIV-infected children on antiretroviral therapy in rural Cameroon: a cross-sectional study.
Zoufaly A; Fillekes Q; Hammerl R; Nassimi N; Jochum J; Drexler JF; Awasom CN; Sunjoh F; Burchard GD; Burger DM; van Lunzen J; Feldt T
Antivir Ther; 2013; 18(5):681-90. PubMed ID: 23502762
[TBL] [Abstract][Full Text] [Related]
5. Patterns of adherence to antiretroviral therapy and HIV drug resistance over time in the Stratall ANRS 12110/ESTHER trial in Cameroon.
Meresse M; March L; Kouanfack C; Bonono RC; Boyer S; Laborde-Balen G; Aghokeng A; Suzan-Monti M; Delaporte E; Spire B; Carrieri MP; Laurent C;
HIV Med; 2014 Sep; 15(8):478-87. PubMed ID: 24589279
[TBL] [Abstract][Full Text] [Related]
6. The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy.
Di Biagio A; Rusconi S; Marzocchetti A; Signori A; Schiavetti I; Bruzzone B; Monno L; Punzi G; Colao MG; Penco G; Zazzi M; De Luca A;
J Med Virol; 2014 Oct; 86(10):1648-55. PubMed ID: 25042976
[TBL] [Abstract][Full Text] [Related]
7. Determinants of virological failure and antiretroviral drug resistance in Mozambique.
Rupérez M; Pou C; Maculuve S; Cedeño S; Luis L; Rodríguez J; Letang E; Moltó J; Macete E; Clotet B; Alonso P; Menéndez C; Naniche D; Paredes R
J Antimicrob Chemother; 2015 Sep; 70(9):2639-47. PubMed ID: 26084302
[TBL] [Abstract][Full Text] [Related]
8. Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study.
Mulu A; Maier M; Liebert UG
PLoS One; 2015; 10(10):e0141318. PubMed ID: 26512902
[TBL] [Abstract][Full Text] [Related]
9. Virological outcome and patterns of HIV-1 drug resistance in patients with 36 months' antiretroviral therapy experience in Cameroon.
Aghokeng AF; Kouanfack C; Eymard-Duvernay S; Butel C; Edoul GE; Laurent C; Koulla-Shiro S; Delaporte E; Mpoudi-Ngole E; Peeters M
J Int AIDS Soc; 2013 Jan; 16(1):18004. PubMed ID: 23374858
[TBL] [Abstract][Full Text] [Related]
10. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies.
Hamers RL; Sigaloff KC; Wensing AM; Wallis CL; Kityo C; Siwale M; Mandaliya K; Ive P; Botes ME; Wellington M; Osibogun A; Stevens WS; Rinke de Wit TF; Schuurman R;
Clin Infect Dis; 2012 Jun; 54(11):1660-9. PubMed ID: 22474222
[TBL] [Abstract][Full Text] [Related]
11. Extraordinary heterogeneity of virological outcomes in patients receiving highly antiretroviral therapy and monitored with the World Health Organization public health approach in sub-saharan Africa and southeast Asia.
Aghokeng AF; Monleau M; Eymard-Duvernay S; Dagnra A; Kania D; Ngo-Giang-Huong N; Toni TD; Touré-Kane C; Truong LX; Delaporte E; Chaix ML; Peeters M; Ayouba A;
Clin Infect Dis; 2014 Jan; 58(1):99-109. PubMed ID: 24076968
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of an affordable HIV-1 virological failure assay and antiretroviral drug resistance genotyping protocol.
Bronze M; Aitken SC; Wallis CL; Steegen K; Stuyver LJ; de Wit TF; Stevens W
J Virol Methods; 2013 Dec; 194(1-2):300-7. PubMed ID: 23994150
[TBL] [Abstract][Full Text] [Related]
13. Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients.
Metzner KJ; Giulieri SG; Knoepfel SA; Rauch P; Burgisser P; Yerly S; Günthard HF; Cavassini M
Clin Infect Dis; 2009 Jan; 48(2):239-47. PubMed ID: 19086910
[TBL] [Abstract][Full Text] [Related]
14. Antiretroviral drug resistance profiles and response to second-line therapy among HIV type 1-infected Ugandan children.
Musiime V; Kaudha E; Kayiwa J; Mirembe G; Odera M; Kizito H; Nankya I; Ssali F; Kityo C; Colebunders R; Mugyenyi P
AIDS Res Hum Retroviruses; 2013 Mar; 29(3):449-55. PubMed ID: 23308370
[TBL] [Abstract][Full Text] [Related]
15. Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.
Cabrera C; Cozzi-Lepri A; Phillips AN; Loveday C; Kirk O; Ait-Khaled M; Reiss P; Kjaer J; Ledergerber B; Lundgren JD; Clotet B; Ruiz L;
Antivir Ther; 2004 Oct; 9(5):787-800. PubMed ID: 15535417
[TBL] [Abstract][Full Text] [Related]
16. Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients.
Barth RE; Aitken SC; Tempelman H; Geelen SP; van Bussel EM; Hoepelman AI; Schuurman R; Wensing AM
Antivir Ther; 2012; 17(2):377-86. PubMed ID: 22297391
[TBL] [Abstract][Full Text] [Related]
17. Short Communication: Population-Based Surveillance of HIV-1 Drug Resistance in Cameroonian Adults Initiating Antiretroviral Therapy According to the World Health Organization Guidelines.
Fokam J; Takou D; Santoro MM; Akonie HZ; Kouanfack C; Ceccherini-Silberstein F; Colizzi V; Perno CF; Ndjolo A
AIDS Res Hum Retroviruses; 2016 Apr; 32(4):329-33. PubMed ID: 26602836
[TBL] [Abstract][Full Text] [Related]
18. Antiretroviral treatment outcome in HIV-1-infected patients routinely followed up in capital cities and remote areas of Senegal, Mali and Guinea-Conakry.
Diouara AA; Ndiaye HD; Guindo I; Bangoura N; Cissé M; Edmond T; Bougoudogo F; Mboup S; Peeters M; Ayouba A; Kane NC
J Int AIDS Soc; 2014; 17(1):19315. PubMed ID: 25527333
[TBL] [Abstract][Full Text] [Related]
19. Characterization of associations and development of atazanavir resistance after unplanned treatment interruptions.
Tinago W; O'Halloran JA; O'Halloran RM; Macken A; Lambert JS; Sheehan GJ; Mallon PW
HIV Med; 2014 Apr; 15(4):224-32. PubMed ID: 24215370
[TBL] [Abstract][Full Text] [Related]
20. Pre-treatment minority HIV-1 drug resistance mutations and long term virological outcomes: is prediction possible?
Mzingwane ML; Tiemessen CT; Richter KL; Mayaphi SH; Hunt G; Bowyer SM
Virol J; 2016 Oct; 13(1):170. PubMed ID: 27733203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
